Market Overview

In Light Of Negative Sentiment, Gilead's Q1 Results Weren't So Bad

Share:
In Light Of Negative Sentiment, Gilead's Q1 Results Weren't So Bad

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent Wednesday morning after the company's first quarter earnings and revenue fell short of what analysts were expecting.

Although Gilead's numbers point to a top-and-bottom line beat, Barclays' Geoff Meacham maintained an Overweight rating with an $85 price target as he believes the report was "acceptable."

Meacham commented in a research report that Gilead's reiteration of its 2017 guidance implies its fundamentals remain stable and aren't worsening. The analyst added that while a better outlook for Gilead's HIV franchise won't be enough to justify a re-rating, it's worth noting that Genvoya is accelerating "dramatically" while bictegravir/TAF could also be a "game-change" in HIV.

Meacham also highlighted some of the negatives aspects of the quarter, including hep C sales which were "very weak" given a 40 percent year-over-year decline and 20 percent quarter-over-quarter decline. The analyst believes this could be attributed to an unfavorable payer mix/competition and this trend is factored into the full-year guidance.

Looking Forward

Meacham stated that Gilead's pipeline of Phase 3 trials (selonsertib, andecaliximab, filgotinib) are "adding up but not quite at a critical mass." But the analyst is still caution on whether positive top-line data could change the overall sentiment on the pipeline favorably.

The analyst also believes a key conversation surrounding Gilead moving forward will be M&A activity. The company's approximately $3 billion in operating cash flow in the first quarter does provide management with lots of optionality and the ability to find a sizable, synergistic, or smart deal that can change the sentiment.

See Also:

Barclays Analyst Pens Open Letter To Gilead Board And Management

Barclays Sees 40% Upside In Versartis Over Next Year

Latest Ratings for GILD

DateFirmActionFromTo
Jan 2020DowngradesBuyNeutral
Dec 2019DowngradesNeutralUnderperform
Nov 2019Initiates Coverage OnHold

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: andecaliximab filgotinib Geoff Meacham Gilead selonsertibAnalyst Color Analyst Ratings Best of Benzinga

 

Related Articles (GILD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
PACWBMO CapitalMaintains37.0
FRBMO CapitalMaintains10.5
COFBMO CapitalMaintains145.0
VRSKBairdMaintains184.0
VBairdMaintains220.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com